New York Senate Bill S06757

New York 2025-2026 Regular Session

• Introduced: 3/24/25
• Refer: 3/24/25
• Engrossed: 6/5/25
• Refer: 6/5/25
• Engrossed: 6/16/25
• Enrolled: 9/22/25
• Chaptered: 9/26/25
• Passed: 9/26/25

Caption

Clarifies that certain provisions related to statewide opioid settlement agreements shall cover settlements and releases related to any entities involved in the prescription drug marketing, supply and payment chain that may have contributed to the opioid epidemic through illegal conduct.

Summary

S06757 amends the Mental Hygiene Law’s definition of “statewide opioid settlement agreements” to broaden the kinds of agreements covered by that term. Under the bill, the definition would no longer be limited to settlements with certain opioid manufacturers, distributors, dispensers, consultants, chain pharmacies, and related entities. Instead, it would encompass statewide agreements entered into by the Attorney General with any party, so long as the agreement resolves claims tied to the manufacture, promotion, dispensing, sale, overutilization, or distribution of opioid products and is consistent with the relevant Executive Law authority. The bill also reinforces the legal effect of these settlements on pending or future government litigation. It states that no government entity may pursue claims that have been released by the Department of Law in a qualifying statewide opioid settlement agreement, and it provides that actions filed after June 30, 2019 asserting those released claims are extinguished by operation of law once the claims are released. The bill takes effect immediately and preserves the Attorney General’s obligation to keep copies of the agreements and related amendments on file for public inspection under the Public Officers Law.

Impact

This bill would expand and clarify the scope of New York’s opioid settlement framework, affecting how state and local governments treat releases negotiated by the Attorney General in statewide opioid-related resolutions. It would likely reduce the ability of municipalities or other government entities to bring or continue lawsuits against parties covered by a statewide settlement release, while also broadening the range of entities that can be included in such settlements beyond the categories specifically listed in prior law. The measure primarily affects the Mental Hygiene Law, with practical consequences for the Department of Law, local governments, and entities in the opioid supply and marketing chain.

Sentiment

The bill appears to have broad support in the Legislature. It passed the Senate Alcoholism and Substance Use Disorders Committee unanimously, then cleared the Senate floor with a substantial majority and the Assembly unanimously. That voting pattern suggests general agreement that the bill is a technical or clarifying measure intended to strengthen and streamline the state’s opioid settlement authority rather than a controversial policy shift.

Contention

The main substantive issue is the breadth of the settlement definition and the preemption of government litigation. Supporters likely view the bill as necessary to ensure that statewide opioid settlements can cover all relevant actors in the prescription drug marketing, supply, and payment chain and to prevent duplicative or conflicting lawsuits by government entities. Any concern would center on whether the expanded language could limit local governments’ ability to pursue claims independently or whether the release-and-extinguishment provisions could be applied too broadly, but the recorded votes indicate little visible opposition in the legislative process.